Idexx Laboratories (IDXX) Cost of Revenue (2009 - 2026)

Idexx Laboratories' Cost of Revenue history runs 18 years deep, the most recent figure standing at $418.1 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 11.47% year-over-year to $418.1 million; the TTM figure through Mar 2026 stood at $1.7 billion (up 10.81% YoY), while the FY2025 annual figure was $1.6 billion, up 8.27% from the prior year.
• Cost of Revenue for Q1 2026 stood at $418.1 million, down from $432.5 million in the prior quarter.
• The five-year high for Cost of Revenue was $432.5 million in Q4 2025, with the low at $335.0 million in Q3 2022.
• The 5-year median for Cost of Revenue is $375.0 million (2025), against an average of $377.3 million.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue declined 0.73% in 2022, then rose 12.73% in 2025.
• Idexx Laboratories' Cost of Revenue stood at $343.6 million in 2022, then advanced by 9.25% to $375.4 million in 2023, then increased by 2.18% to $383.6 million in 2024, then gained by 12.73% to $432.5 million in 2025, then declined by 3.33% to $418.1 million in 2026.
• Business Quant data shows IDXX's Cost of Revenue at $418.1 million in Q1 2026, $432.5 million in Q4 2025, and $421.9 million in Q3 2025.